New cancer clinical trial: A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Published on: December 17, 2018 at 12:00PM
Condition:   Triple Negative Breast Cancer
Interventions:   Drug: JS001，an engineered anti-PD-1 antibody;   Drug: Nab-Paclitaxel;   Drug: Placebo
Sponsors:   CSPC ZhongQi Pharmaceutical Technology Co., Ltd.;   TopAlliance Biosciences, Inc.
Not yet recruiting
https://ift.tt/2SPxWzg